Middle East Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology, By Test Location, By End-use, By Country, And Segment Forecasts, 2025

The Middle East point of care molecular diagnostics market size was valued at USD 273.5 million in 2024 and is projected to reach USD 463.0 million by 2033, growing at a CAGR of 6.13% from 2025 to 2033. The Middle East and Africa (MEA) region encompasses countries with both advanced and emerging healthcare systems, offering a diverse landscape for point-of-care (POC) molecular diagnostics. Well-established healthcare markets, such as Saudi Arabia and the UAE, provide streamlined regulatory pathways, robust logistics, and advanced laboratory networks that support market entry and expansion.

Historically, the region has faced significant challenges with communicable diseases such as malaria and typhoid, and events like the Middle East Respiratory Syndrome (MERS) outbreak in 2015 heightened awareness of the need for rapid molecular diagnostics. The COVID-19 pandemic further accelerated adoption, as the Middle East saw an exponential rise in confirmed cases during early 2020, driving demand for portable and near-patient testing technologies.

Target Disease Prevalence

Governments and private healthcare providers in MEA are strategically investing in infrastructure expansion, from upgrading tertiary hospitals to increasing the number of community-based clinics. These initiatives align with the integration of advanced POC molecular testing platforms capable of delivering fast and accurate results without reliance on centralized laboratories. Economic growth in several Gulf countries, including the UAE, Kuwait, and Qatar, is fueling higher healthcare spending, enabling the adoption of premium diagnostics for infectious diseases, chronic conditions, and sexually transmitted infections (STIs). Moreover, increasing patient awareness, higher purchasing power, and the shift toward preventive and personalized healthcare are expected to sustain market growth in the forecasted period.

In Saudi Arabia, government-led Vision 2030 initiatives emphasize localized manufacturing of molecular diagnostics and expanding public-private partnerships, creating a favorable market for POC platforms in both hospital and community health settings. The UAE is emerging as a regional innovation hub, with AI-enabled diagnostic platforms and ultra-rapid molecular testing solutions developed domestically, such as paper-based devices delivering results in under 10 minutes. Kuwait continues to invest in upgrading laboratory networks, with a growing share of testing shifting toward decentralized formats to improve patient turnaround times. Qatar is channeling resources into early disease detection programs, integrating POC molecular systems into primary care to address chronic and infectious disease burdens. Oman is adopting molecular point-of-care solutions in both urban and rural clinics, driven by national programs targeting respiratory infections, tuberculosis, and other high-prevalence conditions. Collectively, these developments position the Middle East as a rapidly advancing market for point-of-care molecular diagnostics, with strong governmental support and a growing appetite for cutting-edge healthcare technologies.

The UAE is witnessing a rise in the adoption of POC testing due to an increase in government initiatives aimed at the promotion of regular screening activities for cancer and other chronic diseases. For instance, the Ministry of Health and Prevention in the UAE regularly holds breast cancer screening programs, while the Department of Health-Abu Dhabi recommends & encourages frequent screening. Furthermore, the Ministry of Health & Prevention has launched several programs, such as the National Strategy for Fighting Diabetes, for reducing diabetes prevalence in the country.

Middle East Point of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East point-of-care molecular diagnostics market report on the basis of application, technology, test location, end-use, and region:

Technology Outlook (Revenue, USD Million, 2021 - 2033)
PCR-based
Genetic Sequencing-based
Hybridization-based
Microarray-based
Application Type Outlook (Revenue, USD Million, 2021 - 2033)
Infectious Diseases
- HIV POC
- Clostridium difficile POC
- HBV POC
- Pneumonia or Streptococcus associated infections
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Flu POC
- HCV POC
- MRSA POC
- TB and drug-resistant TB POC
- HSV POC
- Other Infectious Diseases
Oncology
Hematology
Prenatal Testing
Endocrinology
Other Applications
Test Location Outlook (Revenue, USD Million, 2021 - 2033)
OTC
POC
End-use Outlook (Revenue, USD Million, 2021 - 2033)
Decentralized Labs
Hospitals
Home-care
Assisted Living Healthcare Facilities
Others
Country Outlook (Revenue, USD Million, 2021 - 2033)
Saudi Arabia
UAE
Kuwait
Qatar
Oman

Product Code: GVR-4-68040-705-6

Chapter 1. Methodology and Scope

1.1. Market Segmentation
- 1.1.1. Market Definitions
1.2. Objectives
- 1.2.1. Objective - 1
- 1.2.2. Objective - 2
- 1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. Gvr's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
- 3.4.1. Growing Demand for Rapid and Decentralized Testing
- 3.4.2. Rising Prevalence of Infectious Diseases
- 3.4.3. Technological Advancements in Molecular Platforms
3.5. Market Restraint Analysis
- 3.5.1. High Cost of Molecular POC Devices and Consumables
- 3.5.2. Regulatory and Quality Assurance Challenges
3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
- 3.6.2. Porter's Five Forces Analysis
- 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

4.1. Middle East Point of Care Molecular Diagnostics market: Technology Movement Analysis
4.2. PCR-based
- 4.2.1. PCR-based Market, 2021 - 2033 (USD Million)
4.3. Genetic Sequencing-based
- 4.3.1. Genetic Sequencing-based Market, 2021 - 2033 (USD Million)
4.4. Hybridization-based
- 4.4.1. Hybridization-based Market, 2021 - 2033 (USD Million)
4.5. Microarray-based
- 4.5.1. Microarray-based Market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

5.1. Middle East Point of Care Molecular Diagnostics Market: Application Movement Analysis
5.2. Infectious Diseases
- 5.2.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
- 5.2.2. HIV POC
  - 5.2.2.1. HIV POC Market, 2021 - 2033 (USD Million)
- 5.2.3. Clostridium difficile POC
  - 5.2.3.1. Clostridium difficile POC Market, 2021 - 2033 (USD Million)
- 5.2.4. HBV POC
  - 5.2.4.1. HBV POC Market, 2021 - 2033 (USD Million)
- 5.2.5. Pneumonia or Streptococcus associated infections
  - 5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2021 - 2033 (USD Million)
- 5.2.6. Respiratory Syncytial Virus (RSV) POC
  - 5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2021 - 2033 (USD Million)
- 5.2.7. HPV POC
  - 5.2.7.1. HPV POC Market, 2021 - 2033 (USD Million)
- 5.2.8. Influenza/Flu POC
  - 5.2.8.1. Influenza/Flu POC Market, 2021 - 2033 (USD Million)
- 5.2.9. HCV POC
  - 5.2.9.1. HCV POC Market, 2021 - 2033 (USD Million)
- 5.2.10. MRSA POC
  - 5.2.10.1. MRSA POC Market, 2021 - 2033 (USD Million)
- 5.2.11. TB and drug-resistant TB POC
  - 5.2.11.1. TB and drug-resistant TB POC Market, 2021 - 2033 (USD Million)
- 5.2.12. HSV POC
  - 5.2.12.1. HSV POC Market, 2021 - 2033 (USD Million)
- 5.2.13. Other Infectious Diseases
  - 5.2.13.1. Other Infectious Diseases Market, 2021 - 2033 (USD Million)
5.3. Oncology
- 5.3.1. Oncology Market, 2021 - 2033 (USD Million)
5.4. Hematology
- 5.4.1. Hematology Market, 2021 - 2033 (USD Million)
5.5. Prenatal Testing
- 5.5.1. Prenatal Testing Market, 2021 - 2033 (USD Million)
5.6. Endocrinology
- 5.6.1. Endocrinology Market, 2021 - 2033 (USD Million)
5.7. Others
- 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Test Location Business Analysis

6.1. Middle East Point of Care Molecular Diagnostics Market: Test Location Movement Analysis
6.2. OTC
- 6.2.1. OTC Market, 2021 - 2033 (USD Million)
6.3. POC
- 6.3.1. POC Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

7.1. Middle East Point of Care Molecular Diagnostics Market: End Use Movement Analysis
7.2. Decentralized Labs
- 7.2.1. Decentralized Labs Market, 2021 - 2033 (USD Million)
7.3. Hospitals
- 7.3.1. Hospitals Market, 2021 - 2033 (USD Million)
7.4. Homecare
- 7.4.1. Home-care Market, 2021 - 2033 (USD Million)
7.5. Assisted Living Healthcare Facilities
- 7.5.1. Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
7.6. Others
- 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

8.1. Middle East Point of Care Molecular Diagnostics Market Share By Region, 2023 & 2033
8.2. MEA
- 8.2.1. MEA Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.2.2. Qatar
  - 8.2.2.1. Key Country Dynamics
  - 8.2.2.2. Target Disease Prevalence
  - 8.2.2.3. Competitive Scenario
  - 8.2.2.4. Regulatory Framework
  - 8.2.2.5. Reimbursement Scenario
  - 8.2.2.6. South Africa Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.2.3. Saudi Arabia
  - 8.2.3.1. Key Country Dynamics
  - 8.2.3.2. Target Disease Prevalence
  - 8.2.3.3. Competitive Scenario
  - 8.2.3.4. Regulatory Framework
  - 8.2.3.5. Reimbursement Scenario
  - 8.2.3.6. Saudi Arabia Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.2.4. UAE
  - 8.2.4.1. Key Country Dynamics
  - 8.2.4.2. Target Disease Prevalence
  - 8.2.4.3. Competitive Scenario
  - 8.2.4.4. Regulatory Framework
  - 8.2.4.5. Reimbursement Scenario
  - 8.2.4.6. UAE Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.2.5. Oman
  - 8.2.5.1. Key Country Dynamics
  - 8.2.5.2. Target Disease Prevalence
  - 8.2.5.3. Competitive Scenario
  - 8.2.5.4. Regulatory Framework
  - 8.2.5.5. Reimbursement Scenario
  - 8.2.5.6. Oman Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.2.6. Kuwait
  - 8.2.6.1. Key Country Dynamics
  - 8.2.6.2. Target Disease Prevalence
  - 8.2.6.3. Competitive Scenario
  - 8.2.6.4. Regulatory Framework
  - 8.2.6.5. Reimbursement Scenario
  - 8.2.6.6. Kuwait Middle East Point of Care Molecular Diagnostics market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant's overview
9.2. Financial performance
9.3. Participant categorization
- 9.3.1. Market Leaders
- 9.3.2. Middle East Point of Care Molecular Diagnostics market Share Analysis, 2023
- 9.3.3. Company Profiles
  - 9.3.3.1. Abbott
    - 9.3.3.1.1. Company Overview
    - 9.3.3.1.2. Financial Performance
    - 9.3.3.1.3. Product Benchmarking
    - 9.3.3.1.4. Strategic Initiatives
  - 9.3.3.2. Bayer AG
    - 9.3.3.2.1. Company Overview
    - 9.3.3.2.2. Financial Performance
    - 9.3.3.2.3. Product Benchmarking
    - 9.3.3.2.4. Strategic Initiatives
  - 9.3.3.3. F. Hoffmann-La Roche AG
    - 9.3.3.3.1. Company Overview
    - 9.3.3.3.2. Financial Performance
    - 9.3.3.3.3. Product Benchmarking
    - 9.3.3.3.4. Strategic Initiatives
  - 9.3.3.4. Nova Biomedical
    - 9.3.3.4.1. Company Overview
    - 9.3.3.4.2. Financial Performance
    - 9.3.3.4.3. Product Benchmarking
    - 9.3.3.4.4. Strategic Initiatives
  - 9.3.3.5. QIAGEN
    - 9.3.3.5.1. Company Overview
    - 9.3.3.5.2. Financial Performance
    - 9.3.3.5.3. Product Benchmarking
    - 9.3.3.5.4. Strategic Initiatives
  - 9.3.3.6. Nipro Diagnostics
    - 9.3.3.6.1. Company Overview
    - 9.3.3.6.2. Financial Performance
    - 9.3.3.6.3. Product Benchmarking
    - 9.3.3.6.4. Strategic Initiatives
  - 9.3.3.7. Danaher
    - 9.3.3.7.1. Company Overview
    - 9.3.3.7.2. Financial Performance
    - 9.3.3.7.3. Product Benchmarking
    - 9.3.3.7.4. Strategic Initiatives
  - 9.3.3.8. Bio-Rad Laboratories, Inc.
    - 9.3.3.8.1. Company Overview
    - 9.3.3.8.2. Financial Performance
    - 9.3.3.8.3. Product Benchmarking
    - 9.3.3.8.4. Strategic Initiatives
  - 9.3.3.9. bioMerieux
    - 9.3.3.9.1. Company Overview
    - 9.3.3.9.2. Financial Performance
    - 9.3.3.9.3. Product Benchmarking
    - 9.3.3.9.4. Strategic Initiatives
  - 9.3.3.10. Agilent Technologies, Inc.
    - 9.3.3.10.1. Company Overview
    - 9.3.3.10.2. Financial Performance
    - 9.3.3.10.3. Product Benchmarking
    - 9.3.3.10.4. Strategic Initiatives
  - 9.3.3.11. Abaxis
    - 9.3.3.11.1. Company Overview
    - 9.3.3.11.2. Financial Performance
    - 9.3.3.11.3. Product Benchmarking
    - 9.3.3.11.4. Strategic Initiatives
  - 9.3.3.12. OraSure Technologies
    - 9.3.3.12.1. Company Overview
    - 9.3.3.12.2. Financial Performance
    - 9.3.3.12.3. Product Benchmarking
    - 9.3.3.12.4. Strategic Initiatives
- 9.3.4. Strategy Mapping
  - 9.3.4.1. Expansion
  - 9.3.4.2. Acquisition
  - 9.3.4.3. Collaborations
  - 9.3.4.4. Disease Type/Drug Class Launch
  - 9.3.4.5. Partnerships
  - 9.3.4.6. Others

Product Code: GVR-4-68040-705-6

List of Tables

TABLE 1 Point-of-care Molecular Diagnostics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
TABLE 2 Middle East Market, by application, 2021 - 2033 (USD Million)
TABLE 3 Middle East Market, by technology, 2021 - 2033 (USD Million)
TABLE 4 Middle East Market, by test location, 2021 - 2033 (USD Million)
TABLE 5 Middle East Market, by end use, 2021 - 2033 (USD Million)
TABLE 6 Middle East Market, by region, 2021 - 2033 (USD Million)
TABLE 7 Point-of-care Molecular Diagnostics- Key market driver analysis
TABLE 8 Point-of-care Molecular Diagnostics- Key market restraint analysis
TABLE 9 Middle East Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
TABLE 10 Middle East Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
TABLE 11 Middle East Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
TABLE 12 Middle East Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
TABLE 13 Middle East Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
TABLE 14 Qatar Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
TABLE 15 Qatar Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
TABLE 16 Qatar Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
TABLE 17 Qatar Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
TABLE 18 Saudi Arabia Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
TABLE 19 Saudi Arabia Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
TABLE 20 Saudi Arabia Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
TABLE 21 Saudi Arabia Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
TABLE 22 UAE Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
TABLE 23 UAE Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
TABLE 24 UAE Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
TABLE 25 UAE Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
TABLE 26 Kuwait Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
TABLE 27 Kuwait Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
TABLE 28 Kuwait Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
TABLE 29 Kuwait Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)

List of Figures

FIG. 1 Middle East Point-Of-Care Molecular Diagnostics Market Segmentation
FIG. 2 Middle East Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
FIG. 3 Middle East Point-Of-Care Molecular Diagnostics Market Dynamics
FIG. 4 Key Opportunities Prioritized, 2018
FIG. 5 Middle East Point-Of-Care Molecular Diagnostics Market - Porter's Analysis
FIG. 6 Middle East Point-Of-Care Molecular Diagnostics Market - PESTEL Analysis
FIG. 7 Middle East Point-Of-Care Molecular Diagnostics Revenue Share, By Application, 2023 & 203
FIG. 8 Middle East POC Molecular Diagnostics Infectious Diseases Market, 2021 - 2033 (USD Million)
FIG. 9 Middle East POC Molecular Diagnostics Oncology Market, 2021 - 2033 (USD Million)
FIG. 10 Middle East POC Molecular Diagnostics Hematology Market, 2021 - 2033 (USD Million)
FIG. 11 Middle East POC Molecular Diagnostics Prenatal Testing Market, 2021 - 2033 (USD Million)
FIG. 12 Middle East POC Molecular Diagnostics Endocrinology Market, 2021 - 2033 (USD Million)
FIG. 13 Middle East POC Molecular Diagnostics Other Applications Market, 2021 - 2033 (USD Million)
FIG. 14 Point-Of-Care Molecular Diagnostics Revenue Share, By Technology, 2023 & 2033
FIG. 15 Middle East POC Molecular Diagnostics PCR-Based Market, 2021 - 2033 (USD Million)
FIG. 16 Middle East POC Molecular Diagnostics Genetic Sequencing-Based Market, 2021 - 2033 (USD Million)
FIG. 17 Middle East POC Molecular Diagnostics Hybridization-Based Market, 2021 - 2033 (USD Million)
FIG. 18 Middle East POC Molecular Diagnostics Microarray-Based Market, 2021 - 2033 (USD Million)
FIG. 19 Point-Of-Care Molecular Diagnostics Revenue Share, By Test Location, 2023 & 2033
FIG. 20 Middle East POC Molecular Diagnostics Over-The-Counter Market, 2021 - 2033 (USD Million)
FIG. 21 Middle East POC Molecular Diagnostics Point-Of-Care Market, 2021 - 2033 (USD Million)
FIG. 22 Point-Of-Care Molecular Diagnostics Revenue Share, By End-Use, 2023 & 2033
FIG. 23 Middle East POC Molecular Diagnostics Decentralized Labs Market, 2021 - 2033 (USD Million)
FIG. 24 Middle East POC Molecular Diagnostics Hospitals Market, 2021 - 2033 (USD Million)
FIG. 25 Middle East POC Molecular Diagnostics Home-Care Market, 2021 - 2033 (USD Million)
FIG. 26 Middle East POC Molecular Diagnostics Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
FIG. 27 Middle East POC Molecular Diagnostics Other Uses Market, 2021 - 2033 (USD Million)
FIG. 28 Point-Of-Care Molecular Diagnostics Revenue Share, By Test Location, 2023 & 2033
FIG. 29 Middle East POC Molecular Diagnostics OTC Market, 2021 - 2033 (USD Million)
FIG. 30 Middle East POC Molecular Diagnostics POC Market, 2021 - 2033 (USD Million)
FIG. 31 Point-Of-Care Molecular Diagnostics Revenue Share, By Region, 2023 & 2033
FIG. 32 Middle East Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
FIG. 33 Qatar Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
FIG. 34 Saudi Arabia Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
FIG. 35 UAE Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
FIG. 36 Kuwait Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
FIG. 37 Oman Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)

Middle East Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology, By Test Location, By End-use, By Country, And Segment Forecasts, 2025 - 2033

Description

Table of Contents

List of Tables

Market Size & Trends:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Technology Business Analysis

Chapter 5. Application Business Analysis

Chapter 6. Test Location Business Analysis

Chapter 7. End Use Business Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

List of Tables

List of Figures